London Declaration on Neglected Tropical Diseases
London Declaration on Neglected Tropical Diseases
The London Declaration on Neglected Tropical Diseases is a significant commitment made by various stakeholders, including governments, non-governmental organizations (NGOs), pharmaceutical companies, and international health organizations, to control, eliminate, or eradicate 10 Neglected Tropical Diseases (NTDs) by the year 2020. Announced in January 2012 in London, the declaration represents a coordinated effort to address diseases that disproportionately affect the world's poorest populations, often in tropical and subtropical regions.
Background
Neglected Tropical Diseases (NTDs) are a group of infectious diseases that prevail in tropical and subtropical conditions in 149 countries, affecting more than one billion people and costing developing economies billions of dollars every year. They include diseases such as Lymphatic Filariasis, Guinea Worm Disease (Dracunculiasis), Leprosy, and Sleeping Sickness (Human African Trypanosomiasis). Despite their impact, NTDs have historically received less attention and funding than other diseases.
Objectives
The main objectives of the London Declaration on Neglected Tropical Diseases are to:
- Sustain or expand existing drug donation programs to meet demand through 2020
- Increase coverage of interventions against NTDs to reach the poorest populations
- Stimulate research and innovation for new treatments
- Enhance collaboration and coordination among stakeholders
Signatories
Key signatories of the declaration include the Bill & Melinda Gates Foundation, the World Health Organization (WHO), the United States Agency for International Development (USAID), the Department for International Development (DFID), and leading pharmaceutical companies such as GlaxoSmithKline, Merck & Co., and Pfizer.
Impact
Since its inception, the London Declaration has mobilized significant resources and fostered partnerships that have led to remarkable progress in the fight against NTDs. Millions of people have received treatments, and several countries have eliminated diseases such as Trachoma and Lymphatic Filariasis as public health problems. The initiative has also spurred innovation in diagnostics and treatments for NTDs.
Challenges and Future Directions
Despite the successes, challenges remain in meeting the 2020 goals, partly due to political instability, conflict zones, and logistical issues in delivering healthcare in remote areas. The COVID-19 pandemic has also posed significant setbacks. Future efforts will need to focus on sustainable healthcare systems, addressing the social determinants of health, and integrating NTD programs with broader health initiatives.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
